Comparison of two investigative assays for the complexed prostate-specific antigen in total prostate-specific antigen between 4.1 and 10.0 ng/mL

Urology

Volumn 55, Issue 5, 2000, Pages 700-704

  Okegawa, Takatsugu ^a,b   Noda, Haruhisa ^a   Nutahara, Kikuo ^a   Higashihara, Eiji ^a  

^a KYORIN UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

AGED; ARTICLE; BLOOD; CLINICAL TRIAL; COMPARATIVE STUDY; HUMAN; MALE; PROSTATE TUMOR; REGRESSION ANALYSIS; SENSITIVITY AND SPECIFICITY;

AGED; HUMANS; MALE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; REGRESSION ANALYSIS; SENSITIVITY AND SPECIFICITY;

EID: 0034182737     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(99)00589-0     Document Type: Article

References (25)

1. Oesterling JE: Prostate specific antigen: a critical assessment of the most useful tumor marker for adenocarcinoma of the prostate. J Urol 145: 907-923, 1991.
2. Benson MC, Whang IS, Olsson CA, et al: The use of prostate specific antigen density to enhance the predictive value of intermediate levels of serum prostate specific antigen. J Urol 147: 817-821, 1992.
3. Osterling JE, Jacobsen LA, Chute CG, et al: Serum prostate specific antigen in a community-based population of healthy man: establishment of age-specific reference ranges. JAMA 270: 860-864, 1993.
4. Catalona WJ, Richie JP, Ahmann FR, et al: Comparison of digital rectal examination and serum prostate specific antigen in the early detection and prostate cancer. J Urol 151: 1283-1290, 1994.
5. Kalish J, Cooner WH, and Graham SD: Serum PSA adjusted for volume of transition zone (PSAT) is more accurate than PSA adjusted of total gland volume (PSAD) in detecting adenocarcinoma of the prostate. Urology 43: 601-606, 1994.
6. Catalona WJ, Smith DS, Wolfert RL, et al: Evaluation of percentage of free serum prostate-specific antigen to improve specificity of prostate cancer screening. JAMA 274: 1214-1220, 1995.
7. Partin AW, Catalona WJ, Southwick PC, et al: Analysis of percentage free prostate-specific antigen (PSA) for prostate cancer detection: influence of total PSA, prostate volume, and age. Urology 48: 55-58, 1996.
8. Catalona WJ, Partin AW, Slawin KM, et al: Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostate disease. JAMA 279: 1542-1547, 1998.
9. Stenman UH, Leinonen J, Alfthan H, et al: A complex between prostate-specific antigen and alpha 1-antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostatic cancer: assay of the complex improves clinical sensitivity for cancer. Cancer Res 51: 222-226, 1991.
10. Lilja H, Christensson A, Dahlen U, et al: Prostate-specific antigen in serum occurs predominantly in complex with α1-antichymotrypsin. Clin Chem 37: 1618-1625, 1991.
11. Lilja H, Cockett ATK, and Abrahamsson P-A: Prostate specific antigen predominantly forms a complex with α1-antichymotrypsin in blood. Cancer 37: 230-234, 1992.
12. Kuriyama M, Ueno K, Yasumasa S, et al: Clinical significance of PSA-alpha-1-antichymotrypsin determination in prostate cancer. Urol Surg 8: 951-958, 1995.
13. 1-antichymotrypsin complex in serum does not improve the differentiation between benign prostatic hyperplasia and prostate cancer compared with total PSA and percent free PSA. Urology 53: 1160-1168, 1999.
14. Bjork T, Piironen T, Pettersson K, et al: Comparison of analysis of the different prostate-specific antigen forms in serum for detection of clinically localized prostate cancer. Urology 48: 882-888, 1996.
15. Wang TJ, Linton HJ, Payne J, et al: Clinical utility of a complexed PSA immunoassay with a specific monoclonal antibody to PSA-ACT. J Urol 157: 147A, 1997.
16. Maeda H, Arai Y, Aoki Y, et al: Complexed prostate-specific antigen and its volume indexes in the detection of prostate cancer. Urology 54: 225-228, 1999.
17. 1-antichymotrypsin complex for the screening and management of prostate cancer. J Clin Lab Anal 12: 32-40, 1998.
18. Espana F, Royo M, Martinez M, et al: Free and complexed prostate specific antigen in the differentiation of benign prostatic hyperplasia and prostate cancer: studies in serum and plasma samples. J Urol 160: 2081-2088, 1998.
19. Allard WJ, Zhou Z, and Yeung KK: Novel immunoassay for the measurement of complexed prostate-specific antigen in serum. Clin Chem 44: 1216-1223, 1998.
20. Brawer MK, Meyer CE, Letran JL, et al: Measurement of complexed PSA improves specificity for early detection of prostate cancer. Urology 52: 372-378, 1998.
21. Brawer MK, Baukson DO, Partin AW, et al: Complexed PSA: results of a multicenter biopsy experience. J Urol 161: 208A, 1999.
22. Sokoll LJ, Bruzek DJ, Cox JL, et al: Is complexed PSA alone clinically useful? J Urol 159(Pt 2): 895A, 1998.
23. Higashihara E, Nutahara K, Kojima M, et al: Significance of serum free prostate specific antigen in the screening of prostate cancer. J Urol 156: 1964-1968, 1996.
24. Hanley JA, and McNeil BJ: Determination of prostate volume by a receiver operating characteristics (ROC) curve. Radiology 143: 29-36, 1982.
25. Hanley JA, and McNeil BJ: A method of comparing the areas under receiver operating characteristics curves derived from the same cases. Radiology 148: 839-843, 1983.